Mobile website
Archive > Volume 31 Issue 9 > 2024,31(9):841-848. DOI:10.3872/j.issn.1007-385X.2024.09.001 Prev Next
Expert Forum
Tumor immunotherapy with mesothelin-targeted drugs: opportunities and challenges
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Tumor immunotherapy is an emerging and promising therapeutic modality. Mesothelin, a cell surface membrane protein anchored by glycosylated phosphatidylinositol, is highly expressed in a variety of malignant solid tumors and hematological malignancies, but lowly expressed in the mesothelial cells of a few normal tissues, making it a promising target for tumor immunotherapy. High mesothelin expression is closely associated with poor prognosis patients, and soluble mesothelin has become a diagnostic biomarker for a variety of tumors. Immunotherapeutic strategies, such as antibody-drug conjugates and CAR-T cell therapy, are undergoing translational research for mesothelin-positive solid tumors, achieving preliminary progress. This paper systematically describes the structure, in vivo distribution, biological functions, and intracellular signaling mechanisms of mesothelin in tumor cells. It also covers targeted imaging and therapeutic strategies based on nuclides, antibody-drug conjugates and CAR-T cells, along with the associated challenges. These insights provide a new perspective for further exploration of mesothelin-targeted immunotherapies.
Keywords:
Project Supported:
Clc Number:
